Situated in Werne, the heart of Germany, Venus Pharma GmbH, a subsidiary of Venus Remedies Limited, completes its 5 years of presence in the Pharmaceutical market of Europe.
Venus received the Century International Quality ERA Award in the Gold Category at Business Initiative Directions (BID) International Quality Convention Geneva 2011
Accredited with World's 15 most stringent GMPs including EU GMP.
73 Patents worldwide including Sulbactomax (our research product) patented all over Europe.
Seven (7) CTD Dossiers ready-Meropenem, Gemcitabine, Irinotecan, Imipenem+Cilastatin, Docetaxel, Sulbactomax & Topotecan.
Proud Owner of Market Authorizations for Meropenem, Imipenem+Cilastatin, Irinotecan and Gemcitabine in Portugal. Also received Market authorization from UK & Poland for Gemcitabine.
Many more Market Authorizations in hand from the ongoing DCP slot of Gemcitabine & Meropenem.
We are backed by our Research & Development Unit in India :
- Duly accredited by Department of Scientific & Industrial Research, DSIR (Govt. of India)
- Having a team of more than 40 scientists
- More than 135 Research Papers published in International Journals,
- Animal house of International Standard duly, accredited by Govt. of India.
- 7 Specialized Testing Laboratories
- Equipped with 8 dedicated Pilot Production Facilities.
Pursuing Site Variation & CTD Development for various Generic European Companies.
QC Laboratories to analyze oncology products as per EU Regulation.
Warehousing facility & Logistic advantage.

Visitors' Appreciation

"Very impressive organization which will achieve great heights. I liked the efficiency and transparancy of execution I dealt with." Anand Kumar Daber Pharma Ltd. India